Pathwork(美國(guó))

Pathwork Diagnostics

美國(guó)PathworkDiagnosticswww.pathworkdx.comPathworkDiagnostics公司是一家從事腫瘤疾病分子診斷技術(shù)研發(fā)的企業(yè)，該公司宣布在一輪融資中獲得來(lái)自Abingworth總額為2000萬(wàn)美元的投資。據(jù)悉，在募資消息宣布前不久，PathworkDiagnostics公司已經(jīng)得到了食品和藥物管理局（FDA）關(guān)于對(duì)一些不確定病原型腫瘤進(jìn)行組織病原測(cè)試的許可，這些 不確定病原腫瘤包括那些低分化，未分化和轉(zhuǎn)移性腫瘤。PathworkDiagnostics,Inc.,isaprivatelyheldcompanyinRedwoodCity,CA,thatdevelopsandcommercializesinnovative,high-valuemoleculardiagnosticsforoncology.Thecompany’sPathwork®TissueofOriginTestisamicroarray-basedgeneexpressiontestthataidsinidentifyingchallengingtumors,includingpoorlydifferentiated,undifferentiated,andmetastaticcancers.ItistheonlyFDA-clearedandMedicare-coveredmoleculartestofitskind.ThecompanyprovidestheTissueofOriginTestthroughitsCLIA-certified,CAP-accreditedlaboratory.IntheU.S.,approximately150,000newlydiagnosedcancerpatientsmayhaveatumorthatismetastatic,undifferentiated,orpoorlydifferentiated,andoftendifficultto